CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 91 enrolled
Drug / intervention
Bupivacaine +1 moredrug
Likely dose
Bupivacaine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06120530
NCT06120530Phase 4Completed
CompareCT.gov

Effect of Intraperitoneal Bupivacaine on Postoperative Pain Control in Patients Undergoing Pelvic Organ Prolapse Repair

Indiana University·interventional·Posted Nov 7, 2023·Updated Apr 20, 2025

In Brief

A Phase 4 clinical trial evaluating Bupivacaine and Saline for Pelvic Organ Prolapse. Completed, enrolled 91 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will decrease postoperative pain scores and opiate consumption in the postoperative period, following pelvic organ prolapse repair.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPelvic Organ Prolapse
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedNov 7, 2023
Enrollment StartAug 16, 2023
Primary CompletionMar 15, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.7 years ago

Interventions

Bupivacainedrug

Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.

Salineother

Placebo